Fritextsökning
Artiklar per år
Innehållstyper
-
Svenskt på topplista över "smarta" sjukhus
Två svenska sjukhus placerar sig på tidskriften Newsweeks topp 100-lista över sjukhusen som är bäst på att använda sig av ny, avancerad medicinsk teknik.
-
Anna Törner: ”Mom, do you think you’ll ever get married again?”
”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence intervals”, Anna Törner writes in a column.
-
“We should avoid surgery if we can”
Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about role models, surgery and Sweden’s strengths and weaknesses in medical research.
-
Ingrid Lönnstedt: ”The confidence interval and its width”
Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be respected, to not have their identity overshadowed by their condition”, writes Anna Törner in a column.
-
The investor: “The major common diseases are hot again”
She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of the industry with Nina Rawal from Trill Impact Advisory.
-
Thumbs down for lecanemab in the EU – “Very surprised”
The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), according to an announcement made by the Agency last week. Bioarctic’s CEO Gunilla Osswald describes the reactions after the announcement as a surprise and disappointment.
-
Healthcare study: Alzheimer’s blood test shows high accuracy
A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.
-
Swedish pavilion with healthcare companies at Ukraine fair – “Ukraine is being rebuilt right now”
Private companies and public authorities are both needed in the reconstruction of Ukraine, said Minister for Health Care, Acko Ankarberg Johansson, in her opening speech in the Swedish pavilion at the ReBuild Ukraine fair.
-
Ranking: Top 10 highest-paid CEOs in pharma
It's nice to hear that things go well for others, right? Some of those who have done really well – at least financially – are listed here in the ranking of the best paid CEOs in Big Pharma 2023.
-
IGN: Marknadsföring av prisvinnande läkemedel var vilseledande
Att framföra att ett läkemedel vunnit ett pris går att tolka som att det är bäst i sin klass, och kan därför vara vilseledande. Det slår Informationsgranskningsnämnden, IGN, fast i ett beslut.
-
Setback for pharmaceutical companies in the Zantac case
A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.
-
Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”
In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 100 years old, he looks back on an intense life and his upbringing in Stockholm, Sweden, which shaped his desire to help the vulnerable in society.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial for maintaining normal haemostasis.
-
“Conducting research at universities is becoming more and more like working at a research hotel”
The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at Lund University, about research policy, the constant hunt for funding in academia and what constitutes ‘fine research’.
-
Bayer has cut 1,500 roles – so far
German chemical and pharmaceutical group Bayer cut more than 1,500 roles in the first quarter alone– and most of them were management positions.
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.
-
List: The coolest names in biotech
Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuticals, a Swedish, or at least Swedish-British, drug came out on top.
-
Lista: Coolaste namnen inom biotech
Håriga bestar, vulkaniskt material och månpromenader sticker ut på en amerikansk lista över de bästa företagsnamnen inom biotech. Och på en annan lista, över de coolaste namnen på läkemedel, blev det svenskt, eller åtminstone svensk-brittiskt, i toppen.
-
Nocebo – the evil twin that makes you feel worse
The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala researcher Charlotte Blease, co-author of a book on the phenomenon.
-
Study: Popular diabetes treatment is not associated with thyroid cancer
Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by an extensive Scandinavian study.
-
Vertex betalar 52 miljarder för bolag inom autoimmuna sjukdomar
Amerikanska Vertex Pharmaceuticals köper biotechbolaget Alpine Immune Sciences för 4,9 miljarder dollar, motsvarande drygt 52 miljarder kronor.
-
Recipharm divests five Swedish plants
Swedish contract manufacturer Recipharm is selling its facilities in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development to US private equity company Blue Wolf Capital Partners.
-
Settlement of cancer allegations against blockbuster drug
French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn drug Zantac allegedly had caused cancer.
BREAKING